Ars Pharmaceuticals [SPRY] vs Liquidia [LQDA] Detailed Stock Comparison
Ars Pharmaceuticals
NASDAQ
Loading...
Liquidia
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Ars Pharmaceuticals wins in 11 metrics, Liquidia wins in 7 metrics, with 0 ties. Ars Pharmaceuticals appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ars Pharmaceuticals | Liquidia | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 168.25 | -13.51 | Liquidia |
| Price-to-Book Ratio | 5.29 | 126.72 | Ars Pharmaceuticals |
| Debt-to-Equity Ratio | 38.28 | 1,319.26 | Ars Pharmaceuticals |
| PEG Ratio | 0.66 | -0.42 | Liquidia |
| EV/EBITDA | -14.51 | -14.31 | Ars Pharmaceuticals |
| Profit Margin (TTM) | -42.74% | 58.00% | Liquidia |
| Operating Margin (TTM) | -302.95% | -424.41% | Ars Pharmaceuticals |
| Return on Equity | -23.56% | -389.13% | Ars Pharmaceuticals |
| Return on Assets (TTM) | -13.85% | -39.74% | Ars Pharmaceuticals |
| Free Cash Flow (TTM) | $12.99M | $-101.87M | Ars Pharmaceuticals |
| 1-Year Return | -29.27% | 106.13% | Liquidia |
| Price-to-Sales Ratio (TTM) | 9.07 | 99.94 | Ars Pharmaceuticals |
| Enterprise Value | $852.39M | $1.96B | Liquidia |
| EV/Revenue Ratio | 7.59 | 101.34 | Ars Pharmaceuticals |
| Gross Profit Margin (TTM) | 68.29% | 83.06% | Liquidia |
| Revenue per Share (TTM) | $1 | $0 | Ars Pharmaceuticals |
| Earnings per Share (Diluted) | $-0.48 | $-1.82 | Ars Pharmaceuticals |
| Beta (Stock Volatility) | 0.84 | 0.16 | Liquidia |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Ars Pharmaceuticals vs Liquidia Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ars Pharmaceuticals | -0.39% | 5.66% | -4.02% | -39.91% | -19.95% | -4.11% |
| Liquidia | 1.92% | 0.26% | -18.30% | 83.61% | 83.91% | 88.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ars Pharmaceuticals | -29.27% | 95.99% | -58.92% | 149.27% | 149.27% | 149.27% |
| Liquidia | 106.13% | 328.89% | 699.30% | 108.01% | 108.01% | 108.01% |
News Based Sentiment: Ars Pharmaceuticals vs Liquidia
Ars Pharmaceuticals
News based Sentiment: MIXED
October presented a mixed bag for ARS Pharmaceuticals, with significant positive developments like Japanese regulatory approval and a substantial loan facility counterbalanced by lowered earnings estimates from William Blair and notable insider selling. This combination of events creates a complex investment picture, making it a moderately important month for investors to reassess their positions.
Liquidia
News based Sentiment: MIXED
Liquidia is facing both opportunities and challenges this month. The potential expansion into the IPF market is a positive catalyst, but the ongoing patent litigation with United Therapeutics and bearish options trading activity introduce significant uncertainty. This creates a mixed investment narrative.
Performance & Financial Health Analysis: Ars Pharmaceuticals vs Liquidia
| Metric | SPRY | LQDA |
|---|---|---|
| Market Information | ||
| Market Cap | $1.03B | $1.93B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,948,990 | 3,320,420 |
| 90 Day Avg. Volume | 3,229,330 | 2,676,227 |
| Last Close | $10.27 | $22.86 |
| 52 Week Range | $9.34 - $18.90 | $9.71 - $29.94 |
| % from 52W High | -45.66% | -23.65% |
| All-Time High | $63.41 (Mar 15, 2021) | $38.46 (Oct 08, 2018) |
| % from All-Time High | -83.80% | -40.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 30.43% | 1.42% |
| Quarterly Earnings Growth | 30.43% | 1.42% |
| Financial Health | ||
| Profit Margin (TTM) | -0.43% | 0.58% |
| Operating Margin (TTM) | -3.03% | -4.24% |
| Return on Equity (TTM) | -0.24% | -3.89% |
| Debt to Equity (MRQ) | 38.28 | 1,319.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.95 | $0.18 |
| Cash per Share (MRQ) | $2.43 | $2.01 |
| Operating Cash Flow (TTM) | $-52,797,000 | $-116,055,000 |
| Levered Free Cash Flow (TTM) | $-26,907,750 | $-71,345,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Ars Pharmaceuticals vs Liquidia
| Metric | SPRY | LQDA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 168.25 | -13.51 |
| Forward P/E | -13.57 | -14.38 |
| PEG Ratio | 0.66 | -0.42 |
| Price to Sales (TTM) | 9.07 | 99.94 |
| Price to Book (MRQ) | 5.29 | 126.72 |
| Market Capitalization | ||
| Market Capitalization | $1.03B | $1.93B |
| Enterprise Value | $852.39M | $1.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.59 | 101.34 |
| Enterprise to EBITDA | -14.51 | -14.31 |
| Risk & Other Metrics | ||
| Beta | 0.84 | 0.16 |
| Book Value per Share (MRQ) | $1.95 | $0.18 |
Financial Statements Comparison: Ars Pharmaceuticals vs Liquidia
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SPRY | LQDA |
|---|---|---|
| Revenue/Sales | $15.72M | $3.12M |
| Cost of Goods Sold | $4.98M | $1.52M |
| Gross Profit | $10.73M | $1.60M |
| Research & Development | $4.04M | $6.97M |
| Operating Income (EBIT) | $-47.61M | $-35.43M |
| EBITDA | $-47.61M | $-33.25M |
| Pre-Tax Income | $-44.88M | $-38.37M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-44.88M | $-38.37M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SPRY | LQDA |
|---|---|---|
| Cash & Equivalents | $39.86M | $169.76M |
| Total Current Assets | $303.86M | $177.21M |
| Total Current Liabilities | $27.62M | $60.52M |
| Long-Term Debt | N/A | $109.66M |
| Total Shareholders Equity | $228.97M | $49.71M |
| Retained Earnings | $-157.25M | $-595.76M |
| Property, Plant & Equipment | $1.15M | $11.49M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SPRY | LQDA |
|---|---|---|
| Operating Cash Flow | $-40.11M | $-26.68M |
| Capital Expenditures | $-91,000 | $-330,000 |
| Free Cash Flow | $-40.83M | $-31.01M |
| Debt Repayment | N/A | $-2.19M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SPRY | LQDA |
|---|---|---|
| Shares Short | 21.58M | 18.47M |
| Short Ratio | 6.96 | 7.92 |
| Short % of Float | 0.36% | 0.27% |
| Average Daily Volume (10 Day) | 2,948,990 | 3,320,420 |
| Average Daily Volume (90 Day) | 3,229,330 | 2,676,227 |
| Shares Outstanding | 97.95M | 84.68M |
| Float Shares | 52.09M | 60.86M |
| % Held by Insiders | 0.17% | 0.13% |
| % Held by Institutions | 0.86% | 0.71% |
Dividend Analysis & Yield Comparison: Ars Pharmaceuticals vs Liquidia
| Metric | SPRY | LQDA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |